Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

Clinical Effects of Discontinuing 5-Alpha Reductase Inhibitor in Patients With Benign Prostatic Hyperplasia

´ëÇѺñ´¢±â°úÇÐȸÁö 2014³â 55±Ç 1È£ p.52 ~ 56
±è¿ø, Á¤ÀçÈï, °­Å¿í, ¼ÛÀ縸, Á¤Çöö,
¼Ò¼Ó »ó¼¼Á¤º¸
±è¿ø ( Kim Won ) 
Yonsei University Wonju College of Medicine Department of Urology

Á¤ÀçÈï ( Jung Jae-Hung ) 
Yonsei University Wonju College of Medicine Department of Urology
°­Å¿í ( Kang Tae-Wook ) 
Yonsei University Wonju College of Medicine Department of Urology
¼ÛÀ縸 ( Song Jae-Mann ) 
Yonsei University Wonju College of Medicine Department of Urology
Á¤Çöö ( Chung Hyun-Chul ) 
Yonsei University Wonju College of Medicine Department of Urology

Abstract


Purpose: To assess changes in lower urinary tract symptoms (LUTS), prostate volume, and serum prostate-specific antigen (PSA) after discontinuation of 5-alpha reductase inhibitor (5ARI) combination therapy in patients with benign prostatic hyperplasia (BPH).

Materials and Methods: From December 2003 to December 2012, data were collected retrospectively from 81 men more than 40 years of age with moderate to severe BPH symptoms (International Prostate Symptom Score [IPSS]¡Ã8). The men were classified into group 1 (n=42) and group 2 (n=39) according to the use of 5ARI therapy. A combination of dutasteride 0.5 mg with tamsulosin 0.2 mg was given daily to all patients for 1 year. For the next 1 year, group 1 (n=42) received the combination therapy and group 2 (n=39) received tamsulosin 0.2 mg monotherapy only. The IPSS, prostate volume, and PSA level were measured at baseline and at 12 and 24 months according to the use of dutasteride.

Results: Discontinuation of dutasteride led to significant deterioration of LUTS, increased prostate volume, and increased PSA level. The repeated-measures analysis of variance showed that the changes in IPSS, prostate volume, and PSA level over time also differed significantly between groups 1 and 2 (p<0.001).

Conclusions: Withdrawal of 5ARI during combination therapy resulted in prostate regrowth and deterioration of LUTS. The PSA level is also affected by the use of 5ARI. Therefore, regular check-up of the IPSS and PSA level may be helpful for all patients who either continue or discontinue the use of 5ARI.

Å°¿öµå

5-Alpha reductase inhibitors; Prostate specific antigen; Prostatic hyperplasia

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS